Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-12
2009-08-11
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S307000, C514S412000, C540S490000, C540S500000, C540S504000, C546S140000, C548S469000
Reexamination Certificate
active
07572783
ABSTRACT:
The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
REFERENCES:
patent: 5438035 (1995-08-01), Guaciaro et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5552524 (1996-09-01), Basinski et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5705515 (1998-01-01), Fisher et al.
patent: 5705890 (1998-01-01), Blackburn et al.
patent: 5739106 (1998-04-01), Rink et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6358951 (2002-03-01), Carpino
patent: 6362331 (2002-03-01), Kamal et al.
patent: 6365633 (2002-04-01), Cheetham et al.
patent: 6602867 (2003-08-01), Starck et al.
patent: 2002/0006964 (2002-01-01), Young et al.
patent: WO99/00123 (1999-01-01), None
patent: WO99/43813 (1999-09-01), None
patent: WO00/21509 (2000-04-01), None
patent: WO00/56721 (2000-09-01), None
patent: WO01/09120 (2001-02-01), None
patent: WO01/10799 (2001-02-01), None
patent: WO01/62341 (2001-08-01), None
patent: WO01/77094 (2001-10-01), None
patent: WO01/89528 (2001-11-01), None
patent: WO02/15845 (2002-02-01), None
patent: WO02/15905 (2002-02-01), None
patent: WO02/40457 (2002-05-01), None
patent: WO02/40487 (2002-05-01), None
patent: WO02/051809 (2002-07-01), None
patent: WO02/076949 (2002-10-01), None
patent: WO02/098865 (2002-12-01), None
patent: WO03/009847 (2003-02-01), None
patent: WO03/041715 (2003-05-01), None
patent: WO2004/002961 (2004-06-01), None
patent: WO2004/021984 (2004-09-01), None
Bray, George A. and Greenway, Frank L., “Current and Potential Drugs for Treatment of Obesity,”Endocrine Reviews, vol. 20, No. 6, pp. 805-875 (1999).
Connacher, A.A., et al., “Weight Loss in Obese Subjects on a Restricted Diet Given BRL 26830A, a New Atypical β Adrenoceptor Agonist,”British Medical Journal, vol. 296, pp. 1217-1220 (1988).
Daniels, A.J., et al., “Food Intake Inhibition and Reduction in Body Weight Gain in Lean and Obese Rodents Treated with GW438014A, a Potent and Selective NPY-Y5 Receptor Antagonist,”Regulatory Peptides, vol. 106 pp. 47-54 (2002).
Gale, Susan M., et al., “Energy Homeostasis, Obesity and Eating Disorders: Recent Advances in Endocrinology,”J. Nutr., vol. 134 No. 2, pp. 295-298 (2004).
Goff, Dane A. and Zuckermann, Ronald N., “Solid-Phase Synthesis of Defined 1,4-Benzodiazepine-2,5-dione Mixtures,”J. Org. Chem., vol. 60, pp. 5744-5745 (1995).
Gualillo, Oreste, et al., Ghrelin, a Widespread Hormone: Insights into Molecular and Cellular Regulation of its Expression and Mechanism of Action,FEBS Letters, vol. 552, pp. 105-109 (2003).
Halaas, J.L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,”Science, vol. 269, pp. 543-546 (1995).
Hataya, Yuji, et al., “A Low Dose of Ghrelin Stimulates Growth Hormone (GH) Release Synergistically with GH-Releasing Hormone in Humans,”Journal of Clinical Endocrinology&Metabolism, vol. 86, No. 9, pp. 4552-4555 (2001).
Kamal, Ahmed, “Enzymatic Approach to the Synthesis of the Pyrrolo[1,4]benzodiazepine Antibiotics,”J. Org. Chem., vol. 56, pp. 2237-2240 (1991).
Keating, Thomas A. and Armstrong, Robert W., “A Remarkable Two-Step Synthesis of Diverse 1,4-Benzodiazepine-2,5-diones Using the Ugi Four-Component Condensation,”J. Org. Chem., vol. 61, pp. 8935-8939 (1996).
Kojima, Masayasu, et al., “Ghrelin is a Growth-Hormone-Releasing Acylated Peptide from Stomach,”Nature, vol. 402, pp. 656-660 (1999).
Kopelman, Peter G., “Obesity as a Medical Problem,”Nature, vol. 404, pp. 635-643 (2000).
Lazewska, D., et al., “Piperidine-containing Histamine H3-receptor Antagonists of the Carbamate Series: Variation of the Spacer Length,”Pharmazie, vol. 56, pp. 927-932 (2001).
Mayer, John P., et al., “Solid Phase Synthesis of 1,4-Benzodiazepine-2,5-diones,”Tetrahedron Letters, vol. 37, No. 45, pp. 8081-8084 (1996).
Mori, Miwako, et al., “A One Step Synthesis of 1,4-Benzodiazepines: Synthetic Studies on Neothramycin,”Tetrahedron Letters, vol. 26, No. 48, pp. 5947-5950 (1985).
Nakazato, Masamitsu, et al., “A Role for Ghrelin in the Central Regulation of Feeding,”Nature, vol. 409, pp. 194-198 (2001).
Peino, Roberto, et al., “Ghrelin-induced Growth Hormone Secretion in Humans,”European Journal of Endocrinology, vol. 143, pp. R11-R14 (2000).
Schwartz, Michael W., et al., “Central Nervous System Control of Food Intake,”Nature, vol. 404, pp. 661-671 (2000).
Strack, Alison M., et al., “Regulation of Body Weight and Carcass Composition by Sibutramine in Rats,”Obesity Research, vol. 10, No. 3, pp. 173-181 (2002).
Sturm, Roland, “The Effects of Obesity, Smoking, and Drinking on Medical Problems and Costs,”Health Affairs, vol. 21, No. 2, pp. 245-253 (2002).
Tschöp, Matthias, et al., “Ghrelin Induces Adiposity in Rodents,”Nature, vol. 407, pp. 908-913 (2000).
Wren, Alison M., et al., “Ghrelin Causes Hyperphagia and Obesity in Rats,”Diabetes, vol. 50, pp. 2540-2547 (2001).
Wren, A.M., et al., “Ghrelin Enhances Appetite and Increases Food Intake in Humans,”The Journal of Clinical Endocrinology&Metabolism, vol. 86, No. 12, pp. 5992-5995 (2001).
Zhang, Puwen, et al., “Synthesis of Novel Imidazobenzodiazepines as Probes of the Phamacophore for ‘Diazepam-Insensitive’ GABAAReceptors,”J. Med. Chem., vol. 38, pp. 1679-1688 (1995).
Zigman, Jeffrey M. and Elmquist, Joel K., “Minireview: From Anorexia to Obesity—The Yin and Yang of Body Weight Control,”Endocrinology, vol. 144, No. 9, pp. 3749-3756 (2003).
International Preliminary Report on Patentability, dated Feb. 13, 2007 of PCT Application No. PCT/US2005/028935, filed Aug. 12, 2005.
Written Opinon, dated Feb. 13, 2007, 2008 of PCT Application No. PCT/US2005/028935, filed Aug. 12, 2005.
Chen Xi
Chen Xiaoqi
Connors Richard Victor
Dai Kang
Fu Ying
Amgen Inc.
Davis Zinna N
Jones Day
LandOfFree
Substituted benzofused heterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzofused heterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzofused heterocycles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126851